venBio Partners

venBio is a life sciences investment firm that partners with industry leaders to build game-changing medicines and technologies.

Business Model:

Revenue: $5.7M

Employees: 2-10

Rankings

Detailed venBio Partners Information

Geographic Data

venBio Partners headquarters map

Address: 1700 Owens St

City: San Francisco

State: CA

Zip: 94158

Country: US

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$2B

Metrics

9,736,746Website Global Rank

107Website Monthly Traffic

Twitter Followers

Description

venBio invests in promising companies at various stages: from early to late stage, and from academic startups to spinouts. We tend to lead most of our investments, and we enjoy building syndicates and teams. We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet their requirements. This includes IP, CMC, and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with.

Contact Phone:
+14158000800

Contact Email:

Announced Date Company Transaction Money Raised
9/2019 Pharvaris Series B 66M
8/2021 Neurogastrx Series B 60M
1/2021 FogPharma Series C 107M
4/2014 Heart Metabolics Series A 20M
6/2018 Akero Therapeutics Series A 65M
12/2013 Stem Cell Therapeutics Post-IPO Equity 0
11/2020 Pharvaris Series C 80M
2/2014 Aurinia Pharmaceuticals Post-IPO Equity 52M
1/2018 Neurogastrx Series A 45M
6/2018 Precision BioSciences Series B 0
1/2022 ImmPACT Bio Series B 0
12/2016 Impel NeuroPharma Series C 36M
2/2016 Apellis Pharmaceuticals Series D 47M
11/2020 Elevation Oncology Series B 65M
9/2020 Attralus Series A 25M
2/2020 ALX Oncology Series C 105M
11/2020 Stargazer Pharmaceuticals Series A 0
12/2018 Akero Therapeutics Series B 70M
6/2020 Artiva Biotherapeutics Series A 0
10/2013 Seragon Pharmaceuticals Series A 30M
9/2015 Outlook Therapeutics Venture Round -
12/2020 Tallac Therapeutics Series A 62M
3/2015 ALX Oncology Series A 36M
10/2020 RayzeBio Series A 45M
12/2018 Impel NeuroPharma Series D 67.5M
1/2022 Ceptur Therapeutics Series A 0
9/2021 Attralus Series B 116M
6/2020 Checkmate Pharmaceuticals Series C 85M
3/2012 Cytos Post-IPO Equity 40M
9/2014 Adaptimmune Series A 0
1/2020 NorthSea Therapeutics Series B 40M
10/2017 Harmony Biosciences Venture Round 0
7/2017 VYNE Therapeutics Series C 50.5M
12/2012 Solstice Biologics Private Equity Round 7.5M
12/2022 Entact Bio Series A 81M
8/2015 Checkmate Pharmaceuticals Series A 20M
9/2021 Ventyx Biosciences Series B 0
1/2013 Labrys Biologics Series A 31M
9/2022 ACELYRIN Series C 0
8/2014 Bellicum Pharmaceuticals Series C 55M
6/2018 Metacrine Series C 65M
4/2019 Arrakis Therapeutics Series B 75M
10/2012 Aragon Pharmaceuticals, Inc. Series D 50M
12/2018 Checkmate Pharmaceuticals Series C 22M
10/2019 Aeovian Pharmaceuticals Series A 0
12/2017 Metacrine Series B 22M
8/2015 Metacrine Series A 36M
11/2021 ACELYRIN Series B 0
6/2017 Checkmate Pharmaceuticals Series B 27M
2/2021 Artiva Biotherapeutics Series B 120M
12/2020 RayzeBio Series B 105M
6/2020 NFlection Therapeutics Series A 20M
8/2017 Apellis Pharmaceuticals Series E 0
12/2021 NorthSea Therapeutics Series C 0
10/2021 CinCor Pharma Series B 0
3/2021 Ventyx Biosciences Series A 0
6/2021 RayzeBio Series C 108M
10/2018 Turning Point Therapeutics Equity 80M
7/2015 Outlook Therapeutics Venture Round 31M
5/2015 Precision BioSciences Series A 0
11/2021 Ablaze Pharmaceuticals Series A 0
10/2021 HistoWiz Series A 32.3M
11/2022 FogPharma Series D 0
1/2013 Solstice Biologics Series A 18M
9/2021 INBRACE Series D 0
10/2019 INBRACE Series C 45M
3/2017 ALX Oncology Convertible Note 25M
2/2015 Cidara Therapeutics Series B 42M
1/2022 ImmPACT Bio Series B 0
1/2022 Ceptur Therapeutics Series A 0
12/2021 NorthSea Therapeutics Series C 0
11/2021 Ablaze Pharmaceuticals Series A 0
11/2021 ACELYRIN Series B 0
10/2021 HistoWiz Series A 0
10/2021 CinCor Pharma Series B 0
9/2021 Ventyx Biosciences Series B 0
9/2021 INBRACE Series D 0
9/2021 Attralus Series B 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research